Alemtuzumab Induction Therapy in Highly Sensitized Kidney Transplant Recipients.
Lu T M, Yang S L, et al.Chinese Medical Journal. 124(5): 664-668, 2011.
Aims
To evaluate the efficacy and safety of alemtuzumab as immune induction therapy in highly sensitized kidney transplant recipients.
Interventions
Anti-thymocyte globulin versus alemtuzumab. All patients received tacrolimus, prednisone and mycophenolate mofetil.
Participants
23 kidney transplant recipients.
Outcomes
The creatinine and blood urea nitrogen, white blood cell counts, patient and allograft survival, acute cellular rejection episodes, cytokine-release syndrome and malignancy development.
Follow-up
12 months
CET Conclusions
Alemtuzumab induction was compared with an anti-thymocyte globulin for induction in allegedly highly sensitised recipients of a renal allograft. However the trial is too small and the lack of definition of highly sensitized patients makes it impossible to draw any conclusions with respect to the use of alemtuzumab in sensitized patients.
Data analysis
Per protocol analysis
Trial registration
Not reported